{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T03:27:36Z","timestamp":1787887656905,"version":"build-2784847793"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100007194","name":"Wenzhou Municipal Science and Technology Bureau","doi-asserted-by":"publisher","award":["Y2020016"],"award-info":[{"award-number":["Y2020016"]}],"id":[{"id":"10.13039\/501100007194","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.ejphar.2021.174689","type":"journal-article","created":{"date-parts":[[2021,12,14]],"date-time":"2021-12-14T11:29:29Z","timestamp":1639481369000},"page":"174689","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Inhibiting STAT5 significantly attenuated Ang II-induced cardiac dysfunction and inflammation"],"prefix":"10.1016","volume":"915","author":[{"given":"Ge","family":"Jin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lintao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2021.174689_bib1","first-page":"62","article-title":"Cardiac remodeling: concepts, clinical impact, pathophysiological mechanisms and pharmacologic treatment","volume":"106","author":"Azevedo","year":"2016","journal-title":"Arq. Bras. Cardiol."},{"key":"10.1016\/j.ejphar.2021.174689_bib2","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.pharmthera.2010.04.005","article-title":"Molecular distinction between physiological and pathological cardiac hypertrophy: experimental findings and therapeutic strategies","volume":"128","author":"Bernardo","year":"2010","journal-title":"Pharmacol. Therapeut."},{"key":"10.1016\/j.ejphar.2021.174689_bib3","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1161\/HYPERTENSIONAHA.111.182154","article-title":"Angiotensin II-induced hypertension is modulated by nuclear factor-kappaBin the paraventricular nucleus","volume":"59","author":"Cardinale","year":"2012","journal-title":"Hypertension"},{"key":"10.1016\/j.ejphar.2021.174689_bib4","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1161\/CIRCULATIONAHA.114.008788","article-title":"Immune cell and other noncardiomyocyte regulation of cardiac hypertrophy and remodeling","volume":"131","author":"Frieler","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.ejphar.2021.174689_bib5","doi-asserted-by":"crossref","first-page":"3002","DOI":"10.1111\/febs.13709","article-title":"The JAK\/STAT pathway in obesity and diabetes","volume":"283","author":"Gurzov","year":"2016","journal-title":"FEBS J."},{"key":"10.1016\/j.ejphar.2021.174689_bib6","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s00395-016-0599-5","article-title":"MD2 mediates angiotensin II-induced cardiac inflammation and remodeling via directly binding to Ang II and activating TLR4\/NF-kappaB signaling pathway","volume":"112","author":"Han","year":"2017","journal-title":"Basic Res. Cardiol."},{"key":"10.1016\/j.ejphar.2021.174689_bib7","doi-asserted-by":"crossref","first-page":"5660","DOI":"10.4049\/jimmunol.1300422","article-title":"IL-2 phosphorylates STAT5 to drive IFN-gamma production and activation of human dendritic cells","volume":"192","author":"Herr","year":"2014","journal-title":"J. Immunol."},{"key":"10.1016\/j.ejphar.2021.174689_bib8","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1161\/HYPERTENSIONAHA.111.172700","article-title":"New take on the role of angiotensin II in cardiac hypertrophy and fibrosis","volume":"57","author":"Kurdi","year":"2011","journal-title":"Hypertension"},{"key":"10.1016\/j.ejphar.2021.174689_bib9","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1161\/CIRCULATIONAHA.113.007101","article-title":"CD4(+) T cells promote the transition from hypertrophy to heart failure during chronic pressure overload","volume":"129","author":"Laroumanie","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.ejphar.2021.174689_bib10","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1161\/CIRCRESAHA.116.304937","article-title":"Mechanotransduction in cardiac hypertrophy and failure","volume":"116","author":"Lyon","year":"2015","journal-title":"Circ. Res."},{"key":"10.1016\/j.ejphar.2021.174689_bib11","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s10741-005-4636-y","article-title":"Left ventricular size and shape: determinants of mechanical signal transduction pathways","volume":"10","author":"Mann","year":"2005","journal-title":"Heart Fail. Rev."},{"key":"10.1016\/j.ejphar.2021.174689_bib12","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1161\/CIRCRESAHA.116.302317","article-title":"Innate immunity and the failing heart the cytokine hypothesis revisited","volume":"116","author":"Mann","year":"2015","journal-title":"Circ. Res."},{"key":"10.1016\/j.ejphar.2021.174689_bib13","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1126\/science.aac7801","article-title":"Immunology. Neutrophil-macrophage communication in inflammation and atherosclerosis","volume":"349","author":"Nahrendorf","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.ejphar.2021.174689_bib14","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/s41569-018-0007-y","article-title":"Mechanisms of physiological and pathological cardiac hypertrophy","volume":"15","author":"Nakamura","year":"2018","journal-title":"Nat. Rev. Cardiol."},{"key":"10.1016\/j.ejphar.2021.174689_bib15","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1161\/CIRCRESAHA.114.300507","article-title":"Angiogenesis and cardiac hypertrophy maintenance of cardiac function and causative roles in heart failure","volume":"114","author":"Oka","year":"2014","journal-title":"Circ. Res."},{"key":"10.1016\/j.ejphar.2021.174689_bib16","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.jchf.2018.06.008","article-title":"Heart failure with preserved ejection fraction expert panel report current controversies and implications for clinical trials","volume":"6","author":"Parikh","year":"2018","journal-title":"JACC Heart Fail."},{"key":"10.1016\/j.ejphar.2021.174689_bib17","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1161\/01.RES.0000047090.08299.D5","article-title":"Tumor necrosis factor-alpha-induced AT1 receptor upregulation enhances angiotensin II-mediated cardiac fibroblast responses that favor fibrosis","volume":"91","author":"Peng","year":"2002","journal-title":"Circ. Res."},{"key":"10.1016\/j.ejphar.2021.174689_bib18","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1089\/jir.2015.0054","article-title":"STAT5 in cancer and immunity","volume":"36","author":"Rani","year":"2016","journal-title":"J. Interferon Cytokine Res."},{"key":"10.1016\/j.ejphar.2021.174689_bib19","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1038\/cr.2014.154","article-title":"STAT5 programs a distinct subset of GM-CSF-producing T helper cells that is essential for autoimmune neuroinflammation","volume":"24","author":"Sheng","year":"2014","journal-title":"Cell Res."},{"key":"10.1016\/j.ejphar.2021.174689_bib20","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.yjmcc.2016.06.001","article-title":"Physiological and pathological cardiac hypertrophy","volume":"97","author":"Shimizu","year":"2016","journal-title":"J. Mol. Cell. Cardiol."},{"key":"10.1016\/j.ejphar.2021.174689_bib21","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1161\/HYPERTENSIONAHA.107.102152","article-title":"Involvement of tumor necrosis factor-alpha in angiotensin II-mediated effects on salt appetite, hypertension, and cardiac hypertrophy","volume":"51","author":"Sriramula","year":"2008","journal-title":"Hypertension"},{"key":"10.1016\/j.ejphar.2021.174689_bib22","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/S1357-2725(02)00271-6","article-title":"Inflammation and angiotensin II","volume":"35","author":"Suzuki","year":"2003","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"10.1016\/j.ejphar.2021.174689_bib23","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1007\/s00204-015-1477-x","article-title":"Pathophysiology of cardiac hypertrophy and heart failure: signaling pathways and novel therapeutic targets","volume":"89","author":"Tham","year":"2015","journal-title":"Arch. Toxicol."},{"key":"10.1016\/j.ejphar.2021.174689_bib24","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1002\/ehf2.12555","article-title":"Highlights in heart failure","volume":"6","author":"Tomasoni","year":"2019","journal-title":"ESC Heart Fail."},{"key":"10.1016\/j.ejphar.2021.174689_bib25","first-page":"1422","article-title":"STAT5 inhibitor attenuates atherosclerosis via inhibition of inflammation: the role of STAT5 in atherosclerosis","volume":"13","author":"Wang","year":"2021","journal-title":"Am. J. Transl. Res."},{"key":"10.1016\/j.ejphar.2021.174689_bib26","doi-asserted-by":"crossref","first-page":"H1638","DOI":"10.1152\/ajpheart.00502.2009","article-title":"Protective actions of estrogen on angiotensin II-induced hypertension: role of central nitric oxide","volume":"297","author":"Xue","year":"2009","journal-title":"Am. J. Physiol.-Heart C"}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299921008451?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299921008451?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T04:17:22Z","timestamp":1762143442000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299921008451"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":26,"alternative-id":["S0014299921008451"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2021.174689","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Inhibiting STAT5 significantly attenuated Ang II-induced cardiac dysfunction and inflammation","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2021.174689","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"174689"}}